{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:33:32Z","timestamp":1790778812630,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014996","name":"Health Commission of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015807","name":"Hangzhou Municipal Health and Family Planning Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003786","name":"Hangzhou Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","giejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastrointestinal Endoscopy"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.gie.2020.04.075","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:54:35Z","timestamp":1589154875000},"page":"1204-1212.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone\u00a0for unresectable extrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"92","author":[{"given":"Jianfeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangbin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gie.2020.04.075_bib1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"Razumilava","year":"2014","journal-title":"Cholangiocarcinoma. Lancet"},{"key":"10.1016\/j.gie.2020.04.075_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/14737140.2014.870480","article-title":"Endoscopic treatment options for cholangiocarcinomas","volume":"14","author":"M\u00f6nkem\u00fcller","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.gie.2020.04.075_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/MEG.0b013e3282f16206","article-title":"Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction","volume":"19","author":"Moss","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gie.2020.04.075_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/j.gastro.2017.06.014","article-title":"Recent advances in endoscopy","volume":"153","author":"Wallace","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gie.2020.04.075_bib5","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1053\/j.gastro.2017.11.295","article-title":"Endoscopic management of pancreatobiliary neoplasms","volume":"154","author":"Wang","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gie.2020.04.075_bib6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00464-013-3232-9","article-title":"Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications","volume":"28","author":"Dolak","year":"2014","journal-title":"Surg Endosc"},{"key":"10.1016\/j.gie.2020.04.075_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1499-3872(13)60066-1","article-title":"Endobiliary radiofrequency ablation for malignant biliary obstruction","volume":"12","author":"Alis","year":"2013","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.gie.2020.04.075_bib8","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s10620-014-3264-6","article-title":"Comparison of metal stenting with radiofrequency ablation versus stenting alone for treating malignant biliary strictures: Is there an added benefit?","volume":"59","author":"Sharaiha","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gie.2020.04.075_bib9","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s10620-015-3731-8","article-title":"Analysis of endoscopic radiofrequency ablation of biliary malignant strictures in pancreatic cancer suggests potential survival benefit","volume":"60","author":"Kallis","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gie.2020.04.075_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1055\/s-0043-124870","article-title":"Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial","volume":"50","author":"Yang","year":"2018","journal-title":"Endoscopy"},{"key":"10.1016\/j.gie.2020.04.075_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.gie.2018.05.006","article-title":"Biliary radiofrequency ablation: burning issues","volume":"88","author":"Chandrasekhara","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gie.2020.04.075_bib12","first-page":"257","article-title":"The efficacy and safety of first-line chemotherapies for advanced biliary tract cancer: a network meta-analysis","volume":"10","author":"Zheng","year":"2019","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.gie.2020.04.075_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000226214","article-title":"S-1 monotherapy in patients with advanced biliary tract cancer","volume":"77","author":"Sasaki","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.gie.2020.04.075_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","article-title":"S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study","volume":"62","author":"Furuse","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.gie.2020.04.075_bib15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/cas.12218","article-title":"Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805)","volume":"104","author":"Morizane","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.gie.2020.04.075_bib16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","article-title":"Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine","volume":"30","author":"Sasaki","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.gie.2020.04.075_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.6004\/jnccn.2009.0027","article-title":"NCCN clinical practice guidelines in oncology: hepatobiliary cancers","volume":"7","author":"Benson","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.gie.2020.04.075_bib18","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106:1-11","author":"Basch","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.gie.2020.04.075_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/MOG.0b013e3283292383","article-title":"A\u00a0conceptual proposal for staging ductal cholangiocarcinoma","volume":"25","author":"Blechacz","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.gie.2020.04.075_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gie.2008.10.039","article-title":"Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years","volume":"70","author":"Cotton","year":"2009","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gie.2020.04.075_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4253\/wjge.v6.i1.13","article-title":"Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction","volume":"6","author":"Tal","year":"2014","journal-title":"World J Gastrointest Endosc"},{"key":"10.1016\/j.gie.2020.04.075_bib22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.ejca.2014.01.008","article-title":"Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma","volume":"50","author":"Park","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gie.2020.04.075_bib23","doi-asserted-by":"crossref","first-page":"8257","DOI":"10.3748\/wjg.v22.i37.8257","article-title":"Review of endoscopic radiofrequency in biliopancreatic tumours with emphasis on clinical benefits, controversies and safety","volume":"22","author":"Alvarez-S\u00e1nchez","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gie.2020.04.075_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-010-1360-7","article-title":"Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy","volume":"67","author":"Sasaki","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.gie.2020.04.075_bib25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26153","article-title":"Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma","volume":"57","author":"Mizukoshi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.gie.2020.04.075_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.gie.2010.09.031","article-title":"Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction","volume":"73","author":"Steel","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gie.2020.04.075_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients","volume":"102","author":"Chuah","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.gie.2020.04.075_bib28","doi-asserted-by":"crossref","first-page":"26888","DOI":"10.18632\/oncotarget.8590","article-title":"Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open label clinical trial","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"}],"container-title":["Gastrointestinal Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016510720342838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016510720342838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:18:12Z","timestamp":1758043092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016510720342838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0016510720342838"],"URL":"https:\/\/doi.org\/10.1016\/j.gie.2020.04.075","relation":{},"ISSN":["0016-5107"],"issn-type":[{"value":"0016-5107","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone\u00a0for unresectable extrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Gastrointestinal Endoscopy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gie.2020.04.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Society for Gastrointestinal Endoscopy","name":"copyright","label":"Copyright"}]}}